Ceribell vs VUNO (2026)
Both give acute care teams an early warning, from different signals. Ceribell reads the brain: a headband EEG placed in minutes, with a machine learning algorithm that estimates seizure burden every ten seconds and alerts at the bedside to suspected status epilepticus, plus a cleared model for delirium. It is cleared by FDA across adults, children and preterm neonates. VUNO's DeepCARS reads the chart: it predicts in hospital cardiac arrest within 24 hours for general ward patients from four routinely charted vital signs and returns a 0 to 100 risk score. It is approved in Korea and carries a CE mark, and it holds FDA Breakthrough Device designation without a US clearance. Choose Ceribell for neurological monitoring where EEG is hard to get; choose VUNO for ward deterioration, noting its US regulatory status.
- Rapid EEG in emergency departments and ICUs, with seizure burden estimated every ten seconds.
- FDA clearances for seizure detection across adults, children and preterm neonates, and for delirium monitoring.
- Remote review by neurologists through a web and mobile portal.
- Prediction of in hospital cardiac arrest within 24 hours from four routinely charted vital signs.
- A 0 to 100 risk score for ward staff and rapid response teams.
- Approval in Korea and a CE mark, with FDA Breakthrough Device designation but no US clearance.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Ceribell and VUNO are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Ceribell | VUNO |
|---|---|---|
| Primary category | Diagnostics & Genomics | Clinical Decision Support |
| Founded | 2014 | 2014 |
| Headquarters | Sunnyvale, California, United States | Seoul, South Korea |
| Website | ceribell.com | vuno.co |
Side by Side
Select any grade to read the note behind it.
Product updates
The latest logged changes from each vendor, newest first, each linked to its source.
Ceribell
-
Regulatory / FDA
Ceribell received FDA 510(k) clearance (K261712) for software that adds Alpha Delta Ratio and Relative Alpha trending, burst suppression monitoring and amplitude integrated EEG to its point of care EEG system.
Source
VUNO
-
Clinical evidence
Researchers from VUNO published a peer-reviewed study in the American Journal of Neuroradiology validating a machine learning algorithm that uses automated brain MRI volumetry to differentiate frontotemporal dementia from Alzheimer's disease.
Source
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Point-of-care EEG company (NASDAQ: CBLL) whose headband and recorder can be placed in minutes in emergency departments and ICUs where conventional EEG and neurology reading are not immediately available. Its Clarity machine learning algorithm reads the EEG every ten seconds to estimate seizure burden and alert at the bedside to suspected status epilepticus, and a second model monitors EEG features associated with delirium; neurologists review recordings remotely through a web and mobile portal.
Source: AI Health Index, September 2026
VUNO, a Seoul medical AI company founded in 2014, leads with DeepCARS, which predicts in-hospital cardiac arrest within 24 hours for patients on general wards from four routinely charted vital signs: blood pressure, heart rate, respiratory rate and temperature. It returns a 0 to 100 risk score for ward staff and rapid response teams to act on, and the company describes it as Korea's first AI medical device for this purpose.
Source: AI Health Index, September 2026
Questions buyers ask
How are Ceribell and VUNO priced and sold?
For Ceribell, the annual report says revenue comes from single-patient headbands and a monthly subscription fee for Clarity, recorders and the portal; the published purchase terms describe purchased and loaned recorders (with a $2,500 charge for a lost or damaged loaned recorder), subscription terms and headband warranties.
With VUNO, the company's history page records that in 2022 DeepCARS became the first AI medical device to enter Korea's non-reimbursed market, and the first designated under the country's early access medical technology route: hospitals can charge patients for it as a non-covered service while its formal evaluation continues. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
What evidence is published for Ceribell and VUNO?
In Ceribell's case, the DECIDE study, a prospective multicenter trial of rapid response EEG's effect on clinical decisions, was published in Critical Care Medicine.
For VUNO, the multicenter validation of 173,368 patients, published in Resuscitation in 2021 and cited on the DeepCARS page, reports an area under the curve of 0.860 internally and 0.905 externally. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Both records were reviewed on this site in September 2026. Neither company publishes a price. DeepCARS has no FDA clearance, so a US hospital should ask about its regulatory path before planning a deployment.
Ask both how many alerts staff receive per true event, and how that was measured.